FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Dacarbazine Injection
Status: Currently in Shortage
»Date first posted: 10/20/2021
»Therapeutic Categories: Oncology

Expand all

Fresenius Kabi USA, LLC (Reverified 11/23/2021)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per vial, Single Dose Amber Vial (NDC 63323-127-10) Backordered. Next release November 2021. Manufacturing delay
200 mg per vial, Single Dose Amber Vial (NDC 63323-128-20) Backordered. Next release November 2021. Manufacturing delay

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 10/27/2021)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
200 mg/vial (NDC 0143-9245-10) This presentation is temporarily on backorder. Additional lots will be available in the beginning of November 2021. Product will be made available as it is released. Demand increase for the drug

Teva Pharmaceuticals (New 10/20/2021)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
200 mg 10x20mL (NDC 00703-5075-03) Limited quantities are available Other
200 mg 1x20mL (NDC 00703-5075-01) Limited quantities are available Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English